MDMA's FDA Rejection: A 1968 Pattern in 2024

“In August 2024, the FDA rejected the MDMA-assisted therapy application for PTSD. The decision was not about efficacy, Phase 3 showed significant results. It was about trial design concerns.”

In June 2024, the FDA's Psychopharmacologic Drugs Advisory Committee voted 10-1 that the evidence did not show MDMA-assisted therapy was effective for PTSD. In August 2024, the FDA issued a Complete Response Letter denying the NDA.

The rejection surprised many. Phase 3 trial data showed 67-71 percent of PTSD patients who received MDMA-assisted therapy no longer met diagnostic criteria at follow-up, compared to approximately 32 percent in the placebo arm.

The FDA's concerns were methodological, not efficacy-based: trials could not adequately blind participants to whether they received active MDMA or placebo; therapist expectancy bias was not controlled; adverse events were inadequately characterized; and trial safety monitoring for drug misuse by therapists was insufficient. An additional Phase 3 trial was requested.

Jay Stevens documented the 1968 collapse of LSD research: a clinical program ended not because the evidence was wrong but because political and institutional conditions became untenable. The MDMA rejection follows a different but related pattern: genuine efficacy evidence found insufficiently methodologically rigorous to approve.

The FDA's request for an additional trial is not a refusal to engage with psychedelic therapy, it is an engagement demanding higher methodological standards than the program delivered. Whether this represents regulatory caution or obstruction depends on one's prior.

Sources

• FDA advisory committee review of the MDMA-assisted therapy application (June 2024)
• MAPS Phase 3 PTSD data
• Psychedelic Legal Status by State 2026